WASHINGTON, DC – January 1, 2013 – SISCAPA Assay Technologies, Inc. (SAT), developer of precision mass spectrometry assays for clinical protein biomarkers, announces two important additions to its leadership team.
Ian Wright joins SAT as a consultant and primary architect of diagnostic business strategy. Previously Ian led a series of key activities at Siemens Healthcare Diagnostics, where he served as head of the Strategic Innovation group, head of Global Assay Development, (leading multi-site groups developing FDA-cleared assays on multiple platforms) and as Core Team Leader for development of the Vista® instrument platform (a program combining routine chemistry, LOCI® homogeneous immunoassay technology, ion-selective electrodes and nephelometry into a broad menu, next-generation, clinical analyzer).
Gustavo “Gus” Salem joins SAT’s Board of Directors, bringing over 20 years of life science sales, marketing, and business management experience. Most recently Gus was Vice-President and General Manager, LC/MS at Agilent Technologies, with responsibility for P&L, product development, and marketing strategy for Agilent’s mass spectrometry business. His previous positions included President and CEO of Assay Designs, a venture-backed life science company developing immunoassays and antibodies for drug discovery research and Division Manager of the Protein Separations Division at Bio-Rad Laboratories, where he managed the P&L, was responsible for the chromatography and electrophoresis product lines and headed the company’s Expression Proteomics program.
“SAT is extremely happy to welcome Ian and Gus to the SISCAPA team”, said Leigh Anderson, SAT’s CEO. “Their collective experience in global diagnostics and mass spectrometry businesses, including both the instrument and reagent components of the diagnostics industry, will help us accelerate the shift from conventional immunoassays to SAT’s high-specificity, multiplexable mass spectrometry-based assay products and services.”
About SISCAPA Assay Technologies, Inc.
SISCAPA Assay Technologies Inc. (SAT) delivers high-sensitivity, high-throughput specific assays for clinical protein biomarkers using SISCAPA® affinity-MS technology. Additional information about SISCAPA technology, reagents and business opportunities is available at www.SISCAPA.com
For more information contact Leigh Anderson at (301) 728-1451
